Jane Street Group LLC Buys 111,917 Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL)

Jane Street Group LLC increased its holdings in shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) by 63.7% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 287,717 shares of the company’s stock after purchasing an additional 111,917 shares during the period. Jane Street Group LLC owned approximately 0.10% of Lyell Immunopharma worth $397,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of LYEL. State Street Corp raised its stake in shares of Lyell Immunopharma by 1.9% in the third quarter. State Street Corp now owns 3,889,553 shares of the company’s stock valued at $5,368,000 after purchasing an additional 71,233 shares in the last quarter. TD Asset Management Inc lifted its position in shares of Lyell Immunopharma by 4.2% during the second quarter. TD Asset Management Inc now owns 1,004,642 shares of the company’s stock worth $1,457,000 after purchasing an additional 40,800 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in Lyell Immunopharma by 6.1% in the second quarter. Bank of New York Mellon Corp now owns 671,966 shares of the company’s stock valued at $974,000 after acquiring an additional 38,487 shares during the last quarter. The Manufacturers Life Insurance Company lifted its holdings in Lyell Immunopharma by 14.4% in the second quarter. The Manufacturers Life Insurance Company now owns 553,163 shares of the company’s stock valued at $802,000 after buying an additional 69,712 shares during the period. Finally, GSA Capital Partners LLP lifted its stake in Lyell Immunopharma by 1,285.5% in the third quarter. GSA Capital Partners LLP now owns 354,815 shares of the company’s stock valued at $490,000 after buying an additional 329,205 shares during the period. Institutional investors own 66.05% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on LYEL. Bank of America lowered shares of Lyell Immunopharma from a “buy” rating to an “underperform” rating and cut their target price for the stock from $6.00 to $1.00 in a report on Wednesday, October 30th. HC Wainwright reaffirmed a “neutral” rating and set a $1.00 price objective on shares of Lyell Immunopharma in a research note on Tuesday, November 12th.

Lyell Immunopharma Price Performance

NASDAQ:LYEL opened at $0.66 on Wednesday. The business’s 50-day simple moving average is $0.89 and its 200-day simple moving average is $1.22. Lyell Immunopharma, Inc. has a fifty-two week low of $0.58 and a fifty-two week high of $3.26. The stock has a market capitalization of $193.85 million, a PE ratio of -0.84 and a beta of -0.35.

Lyell Immunopharma (NASDAQ:LYEL) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.03. Lyell Immunopharma had a negative net margin of 323,792.09% and a negative return on equity of 34.64%. The firm had revenue of $0.03 million for the quarter. On average, research analysts expect that Lyell Immunopharma, Inc. will post -0.78 earnings per share for the current year.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.